scholarly journals Accuracy of injection and short-term pain relief following intra-articular corticosteroid injection in knee osteoarthritis – an observational study

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
G. Hirsch ◽  
T. W. O’Neill ◽  
G. Kitas ◽  
A. Sinha ◽  
R. Klocke
Keyword(s):  
Pain Relief ◽  
Observational Study ◽  
Knee Osteoarthritis ◽  
Corticosteroid Injection ◽  
Short Term

MEDIUM-TERM OUTCOME FOLLOWING INTRA-ARTICULAR CORTICOSTEROID INJECTION IN FIRST CMC JOINT ARTHRITIS USING FLUOROSCOPY

Hand Surgery ◽  
2009 ◽  
Vol 14 (02n03) ◽  
pp. 99-104 ◽  
Author(s):  
Wies Maarse ◽  
Adam C. Watts ◽  
Gregory I. Bain
Keyword(s):  
Pain Relief ◽  
Surgical Intervention ◽  
Corticosteroid Injection ◽  
Carpometacarpal Joint ◽  
Medium Term ◽  
Short Term ◽  
Term Outcome ◽  
Joint Arthritis ◽  
Local Corticosteroid Injection

First carpometacarpal joint osteoarthritis (1st CMCJ OA) is a common condition with variable results reported from local corticosteroid injection. This study aims to explore the medium-term outcome with respect to pain relief, patient satisfaction and the need for subsequent surgical intervention. A prospective review was performed of patients undergoing fluoroscopically guided corticosteroid injection by one surgeon, with postal questionnaires for medium-term follow-up. Forty-one patients were included. Thirty-one were female and ten male, with a mean age of 60 years. In the short term 76% of patients reported pain relief with an average duration of four weeks and 69% of the patients reported benefit from injection. After a median follow-up of 36 months 76% of patients reported continuing pain but 59% reported satisfaction with the outcome. Twenty-eight per cent of the patients had undergone surgery. Local corticosteroid injection of the CMCJ provides only short-term pain relief, but few patients go on to surgical intervention.

scholarly journals Comparison of the short-term results of single-dose intra-articular peptide with hyaluronic acid and platelet-rich plasma injections in knee osteoarthritis: a randomized study

2020 ◽  
Vol 39 (10) ◽  
pp. 3057-3064 ◽  
Author(s):  
Fatma Nur Kesiktas ◽  
Bahar Dernek ◽  
Ekin Ilke Sen ◽  
Havva Nur Albayrak ◽  
Tugba Aydin ◽  
...  
Keyword(s):  
Pain Relief ◽  
Knee Osteoarthritis ◽  
Platelet Rich Plasma ◽  
Randomized Study ◽  
Functional Improvement ◽  
Womac Pain ◽  
Peptide Group ◽  
Short Term ◽  
Womac Pain Score ◽  
The Third

Abstract Introduction/objectives Intra-articular injections may be useful in terms of pain and functional status, in knee osteoarthritis (OA). Besides hyaluronic acid (HA) and platelet-rich plasma (PRP), peptide molecules recently begin to be used. The aim of this study was to compare the efficacy of intra-articular peptide Prostrolane® (CAREGEN Co. Ltd.) injection with that of the HA and PRP in the persons with OA. Method Fifty-four patients with OA were included in this prospective, randomized study. Patients were randomized into three groups as intra-articular HA, peptide, and PRP groups. Paracetamol was permitted three times a day to all groups. All the patients were evaluated by the Western Ontario and McMaster Universities Arthritis Index (WOMAC), Health Assessment Questionnaire (HAQ), and visual analogue scale (VAS) at rest and during movements. Measurements performed at the baseline, after the first week of injection, and at the first and third months of follow-up. Results Mean age was 55.8 ± 8.9 years. Forty-four (81.6%) were women. A week after the injections, rest and movement pain severity was measured by VAS decreased significantly in all the study groups (p < 0.05). There were no statistically significant differences between the groups in terms of first week pain relief (p > 0.05). WOMAC pain, stiffness, function, and total scores were improved significantly in all the groups a week after the injections (p < 0.05). Improvement continued at the third month control; however, the improvement in the WOMAC pain score was significantly better in the peptide group at the third month control (p < 0.05). The decrease in the rest and movement pain was continued for 3 months except the HA group’s rest pain. There were no differences among the groups for all measurements, except for the WOMAC pain score at 3 months after treatment, which was significantly lower in the peptide group. Conclusion As a result, pain relief and functional improvement were obtained after the intra-articular HA, peptide, and PRP injections in OA, and decrease in pain was better in the peptide group. Key Points• The short-term effects of intra-articular HA, peptide, and PRP injections were compared in knee osteoarthritis.• HA, peptide, and PRP injections may be useful in pain relief and functional improvement in knee osteoarthritis.

scholarly journals Efficacy of injection of steroids for lateral epicondylitis

1970 ◽  
Vol 32 (3) ◽  
pp. 34-38
Author(s):  
R Maharjan ◽  
G Gurung
Keyword(s):  
Placebo Group ◽  
Pain Relief ◽  
Single Injection ◽  
Tennis Elbow ◽  
Corticosteroid Injection ◽  
Lateral Epicondylitis ◽  
Local Injection ◽  
Long Term Effects ◽  
Short Term

Introduction: Lateral epicondylitis (Tennis elbow) is one of the most common lesions of the arm. Corticosteroid injection has been described as one of the treatment modalities for this disorder with variable clinical benefit. The purpose of this study was to analyze the short-term and long-term effects of the local injection of methylprednisolone to treat lateral epicondylitis. Methods: A prospective comparative study was carried out in the Department of Orthopaedics in Bir Hospital from October 2009 to February 2011. Study was undertaken in 40 patients to analyze the short-term and long-term effects of the local injection of methylprednisolone for the treatment of lateral epicondylitis. Twenty patients in each group were included in the study. Patients assigned to experimental group received a single injection of 1 percent lidocaine with forty milligrams of methylprednisolone and control group received a single injection of 1 percent lidocaine with saline solution. Results: Corticosteroid injection gave better pain relief in a shorter time than the placebo group. Pain was significantly improved in steroid group in comparison to placebo group till third successive follow ups with maximum improvement at eighteen weeks (p=0.000). However, the groups did not differ with regards to pain at six months as determined with a clinical pain score and visual analogue scale. Conclusions: Local injections of steroids provide rapid pain relief but only short-term benefits in the treatment of lateral epicondylitis. Key word: Epicondylities; Steroid injection; tennis elbow DOI: http://dx.doi.org/10.3126/joim.v32i3.4958 Journal of Institute of Medicine, December, 2010; 32:3 34-38

scholarly journals COMPARISON OF PAIN RELIEF EFFICACY OF PLATELET-RICH PLASMA VERSUS CORTICOSTEROIDS IN KNEE OSTEOARTHRITIS

2021 ◽  
Vol 71 (5) ◽  
pp. 1764-68
Author(s):  
Amir Sohail ◽  
Ameer Yasser Zaid ◽  
Shizan Hamid Feroz ◽  
Mohammed Saeed ◽  
Syed Khurram Naseer ◽  
...  
Keyword(s):  
Pain Relief ◽  
Knee Osteoarthritis ◽  
Rating Scale ◽  
Platelet Rich Plasma ◽  
Corticosteroid Injection ◽  
Numeric Rating Scale ◽  
Rating Score ◽  
Numerical Rating ◽  
Group A ◽  
Group B

Objective: To compare the pain relief efficacy of platelet rich plasma injection with corticosteroid injection in knee osteoarthritis using numeric rating scale. Study Design: Quasi experimental study. Place and Duration of Study: Department of Anesthesia and Pain Management, Combined Military Hospital Peshawar, from Jan 2018 to Dec 2019. Methodology: Total of 310 patients who underwent knee injection for osteoarthritis were included in this study. Patients were divided into two groups; group A and group B comprising of 155 patients each. Patients in group ‘A’ received intra articular corticosteroid injection while patients in group ‘B’ received intra articular platelet rich plasma injection for knee osteoarthritis. Pain assessment via numerical rating score was done at the start of the treatment and at 6 months. Results: In group A female to male ratio was 2.69:1 while in group B the female to male ratio was 2.78:1. Mean age of ‘group A’ was 58.52 ± 11.87 years and that of ‘group B’ was 58.79 ± 11.15 years. Numerical rating score pre-treatment in ‘group A’ vs ‘group B’ was 8.35 ± 1.17 vs 8.42 ± 1.14. While numeric rating scale post treatment in ‘group A’ vs ‘group B’ was 5.74 ± 1.37 vs 4.06 ± 1.19, respectively with p-value of 0.001, which is statistically significant. Conclusion: Patients who received intra-articular platelet rich plasma had significantly more pain relief as compared to patients who received intra-articular steroid on numerical rating score.

Short-Term Pain Relief by Repetitive Peripheral Magnetic Stimulation in Patients with Musculoskeletal Pain: A Pilot Study

Clinical Pain ◽  
2020 ◽  
Vol 19 (1) ◽  
pp. 16-22
Author(s):  
Joonhyun Park ◽  
Hyunseok Kwak ◽  
Wookyung Park ◽  
MinYoung Kim ◽  
Kyunghoon Min
Keyword(s):  
Pilot Study ◽  
Pain Relief ◽  
Musculoskeletal Pain ◽  
Magnetic Stimulation ◽  
Short Term

scholarly journals The relationship between maximal expiratory pressure values and critical outcomes in mechanically ventilated patients: a post hoc analysis of an observational study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yann Combret ◽  
Guillaume Prieur ◽  
Roger Hilfiker ◽  
Francis-Edouard Gravier ◽  
Pauline Smondack ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Observational Study ◽  
Univariate Analysis ◽  
Premature Death ◽  
Extubation Failure ◽  
Short Term ◽  
Expiratory Muscle ◽  
Maximal Expiratory Pressure ◽  
The Impact ◽  
The Relationship

Abstract Background Little interest has been paid to expiratory muscle strength, and the impact of expiratory muscle weakness on critical outcomes is not known. Very few studies assessed the relationship between maximal expiratory pressure (MEP) and critical outcomes. The aim of this study was to investigate the relationship between MEP and critical outcomes. Methods This work was a secondary analysis of a prospective, observational study of adult patients who required mechanical ventilation for ≥ 24 h in an 18-bed ICU. MEP was assessed before extubation after a successful, spontaneous breathing trial. The relationships between MEP and extubation failure, and short-term (30 days) mortality, were investigated. Univariate logistic regressions were computed to investigate the relationship between MEP values and critical outcomes. Two multivariate analyses, with and without maximal inspiratory pressure (MIP), both adjusted using principal component analysis, were undertaken. Unadjusted and adjusted ROC curves were computed to compare the respective ability of MEP, MIP and the combination of both measures to discriminate patients with and without extubation failure or premature death. Results One hundred and twenty-four patients were included. Median age was 66 years (IQR 18) and median mechanical ventilation duration was 7 days (IQR 6). Extubation failure rate was 15% (18/124 patients) and the rate for 30-day mortality was 11% (14/124 patient). Higher MEP values were significantly associated with a lower risk of extubation failure in the univariate analysis [OR 0.96 95% CI (0.93–0.98)], but not with short-term mortality. MEP was independently linked with extubation failure when MIP was not included in the multivariate model, but not when it was included, despite limited collinearity between these variables. This study was not able to differentiate the respective abilities of MEP, MIP, and their combination to discriminate patients with extubation failure or premature death (adjusted AUC for the combination of MEP and MIP: 0.825 and 0.650 for extubation failure and premature death, respectively). Conclusions MEP is related to extubation failure. But, the results did not support its use as a substitute for MIP, since the relationship between MEP and critical outcomes was no longer significant when MIP was included. The use of MIP and MEP measurements combined did not reach higher discriminative capacities for critical outcomes that MEP or MIP alone. Trial Registration This study was retrospectively registered at https://clinicaltrials.gov/ct2/show/NCT02363231?cond=NCT02363231&draw=2&rank=1 (NCT02363231) in 13 February 2015

Sign in / Sign up

Export Citation Format

Share Document